Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Mainz Biomed NV MYNZ

Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.


NDAQ:MYNZ - Post by User

Bullboard Posts
Next >>
User Avatar Image
(292)
•••
  • whytestocksX
Post by whytestockson May 28, 2024 12:30pm
77 Views
Post# 36060552

Mainz Biomed to Present New Pooled Colorectal Cancer Screeni

Mainz Biomed to Present New Pooled Colorectal Cancer Screeni
JUST IN: $MYNZ Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting | BenzingaKey Findings: 92.3% Sensitivity for Colorectal Cancer, 82.3% for Advanced Precancerous LesionsPoster presentation showing new data on 690 subject...MYNZ - Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting | Benzinga



Bullboard Posts
Next >>